Sch35966 is a potent, selective agonist at the peripheral cannabinoid receptor (CB 2) in rodents and primates

British Journal of Pharmacology

Volumn 151, Issue 8, 2007, Pages 1262-1271

  Gonsiorek, W ^a   Lunn, C A ^a   Fan, X ^a   Deno, G ^a   Kozlowski, J ^a   Hipkin, R W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CB 2 selective agonist; Peripheral cannabinoid receptor; Sch35966

Indexed keywords

8,10 BIS[(2,2 DIMETHYL 1 OXOPROPYL)OXY] 11 METHYL 1234 TETRAHYDRO 6H BENZO[BETA]QUINOLIZIN 6 ONE; BENZOQUINONE DERIVATIVE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CYCLIC AMP; FORSKOLIN; LIGAND; SCH 35966; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING ASSAY; CELL MEMBRANE; CHEMOTAXIS; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; MONKEY; MOUSE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RODENT;

ANIMALS; BINDING, COMPETITIVE; CELL MEMBRANE; CHEMOTAXIS; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; CYCLOHEXANOLS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; INDOLES; MACACA FASCICULARIS; MICE; QUINOLIZINES; RATS; RECEPTOR, CANNABINOID, CB2; SPECIES SPECIFICITY; TETRAHYDROCANNABINOL;

EID: 34547924400     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707336     Document Type: Article

References (55)

1. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT et al. (2003). Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med 139: 258-266.
2. Bayewitch M, Avidor-Reiss T, Levy R, Barg J, Mechoulam R, Vogel Z (1995). The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett 375: 143-147.
3. Bayewitch M, Rhee MH, Avidor-Reiss T, Breuer A, Mechoulam R, Vogel Z (1996). (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem 271: 9902-9905.
4. Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S et al. (2006). CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 23: 1530-1538.
5. Bouaboula M, Poinot-Chazel C, Bourrie B, Canat X, Calandra B, Rinaldi-Carmona M et al. (1995). Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 312: 637-641.
6. 2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem 237: 704-711.
7. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
8. 35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J Biol Chem 273: 16865-16873.
9. Cabral GA, Toney DM, Fischer-Stenger K, Harrison MP, Marciano-Cabral F (1995). Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells. Life Sci 56: 2065-2072.
10. Cheng Y, Prusoff WH (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
11. Chin C, Murphy J, Huffman J, Kendall DA (1999). The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. J Pharmacol Exp Ther 291: 837-844.
12. Chou CC, Fine JS, Pugliese-Sivo C, Gonsiorek W, Davies L, Deno G et al. (2002). Pharmacological characterization of the chemokine receptor, hCCR1 in a stable transfectant and differentiated HL-60 cells: antagonism of hCCR1 activation by MIP-1β. Br J Pharmacol 137: 663-675.
13. Clayton N, Marshall FH, Bountra C, O'Shaughnessy CT (2002). CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 96: 253-260.
14. Correa F, Mestre L, Docagne F, Guaza C (2005). Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br J Pharmacol 145: 441-448.
15. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949.
16. Di Marzo V, Bisogno T, De Petrocellis L, Melck D, Orlando P, Wagner JA et al. (1999). Biosynthesis and inactivation of the endocannabinoid 2- arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem 264: 258-267.
17. Ferrali A, Menchi G, Occhiato EG, Danza G, Mancina R, Serio M et al. (2005). Synthesis and activity of 8-substituted benzo[c]quinolizin-3- ones as dual inhibitors of human 5alpha-reductases 1 and 2. Bioorg Med Chem Lett 15: 145-148.
18. Friary RJUS (1990). Benzoquinolizinones as antiallergic, antiinflammatory, and antihyperproliferative agents and their preparation. US 4897391.
19. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P et al. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232: 54-61.
20. Gerard CM, Mollereau C, Vassart G, Parmentier M (1991). Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 279: 129-134.
21. Glass M, Felder CC (1997). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 17: 5327-5333.
22. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW (2000). Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol 57: 1045-1050.
23. Govaerts SJ, Hermans E, Lambert DM (2004). Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors. Eur J Pharm Sci 23: 233-243.
24. 2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96: 14228-14233.
25. Hipkin RW, Friedman J, Clark RB, Eppler CM, Schonbrunn A (1997). Agonist-induced desensitization, internalization, and phosphorylation of the sst2A somatostatin receptor. J Biol Chem 272: 13869-13876.
26. Hohmann AG, Farthing JN, Zvonok AM, Makriyannis A (2004). Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther 308: 446-453.
27. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161-202.
28. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A et al. (2005). CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 102: 3093-3098.
29. Jenck F, Moreau JL, Bonetti EP, Martin JR, Haefely WE (1992). Ro 19-8022, a nonbenzodiazepine partial agonist at benzodiazepine receptors: neuropharmacological profile of a potential anxiolytic. J Pharmacol Exp Ther 262: 1121-1127.
30. Kaminski NE (1996). Immune regulation by cannabinoid compounds through the inhibition of the cyclic AMP signaling cascade and altered gene expression. Biochem Pharmacol 52: 1133-1140.
31. Kaminski NE (1998). Regulation of the cAMP cascade, gene expression and immune function by cannabinoid receptors. J Neuroimmunol 83: 124-132.
32. Katona S, Kaminski E, Sanders H, Zajicek J (2005). Cannabinoid influence on cytokine profile in multiple sclerosis. Clin Exp Immunol 140: 580-585.
33. 2 receptor-dependent mechanism. J Biol Chem 278: 24469-24475.
34. Klein TW, Newton C, Friedman H (1998). Cannabinoid receptors and the cytokine network. Adv Exp Med Biol 437: 215-222.
35. LaBuda CJ, Koblish M, Little PJ (2005). Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain. Eur J Pharmacol 527: 172-174.
36. Lavey BJ, Kozlowski JA, Hipkin RW, Gonsiorek W, Lundell DJ, Piwinski JJ et al. (2005). Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies. Bioorg Med Chem Lett 15: 783-786.
37. Lee M, Yang KH, Kaminski NE (1995). Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. J Pharmacol Exp Ther 275: 529-536.
38. Lunn CA, Fine JS, Rojas-Triana A, Jackson JV, Fan X, Kung TT et al. (2006). J Pharmacol Exp Ther 316: 780-788.
39. Malan Jr TP, Ibrahim MM, Vanderah TW, Makriyannis A, Porreca F (2002). Inhibition of pain responses by activation of CB(2) cannabinoid receptors. Chem Phys Lipids 121: 191-200.
40. Malan Jr TP, Ibrahim MM, Lai J, Vanderah TW, Makriyannis A, Porreca F (2003). CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol 3: 62-67.
41. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
42. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83-90.
43. Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65.
44. Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Porreca F, Makriyannis A et al. (2003). Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 99: 955-960.
45. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A et al. (1999). Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol 126: 665-672.
46. 2 receptors. J Neuroimmunol 109: 155-163.
47. Schatz AR, Lee M, Condie RB, Pulaski JT, Kaminski NE (1997). Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol 142: 278-287.
48. Showalter VM, Compton DR, Martin BR, Abood ME (1996). Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J P 278: 989-999.
49. Slipetz DM, O'Neill GP, Favreau L, Dufresne C, Gallant M, Gareau Y et al. (1995). Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol 48: 352-361.
50. Smith SR, Denhardt G, Terminelli C (2001a). The anti-inflammatory activities of cannabinoid receptor ligands in mouse peritonitis models. Eur J Pharmacol 432: 107-119.
51. Smith SR, Terminelli C, Denhardt G (2000) Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther 293: 136-150.
52. Smith SR, Terminelli C, Denhardt G (2001b). Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands. Eur J Pharmacol 425: 73-83.
53. Stout GW, Stott CG (2005). The development of Sativex - a natural cannabis-based medicine. Cannabinoids as Therapeutics. In: Mechoulam R (ed). Birkhauser Verlag: Basel, Boston, Berlin, pp 231-263.
54. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K et al. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215: 89-97.
55. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K et al. (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310: 329-332.